MedWatch

Leo Pharma disappoints as deficit surpasses USD 720m

Leo Pharma’s deficit increased fivefold in 2021 to a bottom line result of DKK 4.9bn (USD 726.6m). Acting CEO Anders Kronborg acknowledges that this looks very disappointing, but says that the company has a plan to turn things around as early as next year.

Photo: MAGNUS MØLLER

Revenues are down as the bottom line deficit at Leo Pharma grows, the company’s annual report for 2021 reveals.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

China approves Y-mabs drug

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

See all jobs